As­traZeneca's lung can­cer block­buster Tagris­so wins la­bel ex­pan­sion in ear­ly-stage EGFR pa­tients

As­traZeneca’s block­buster lung can­cer treat­ment Tagris­so scored a new FDA ap­proval on Thurs­day in cer­tain EGFR-mu­tat­ed ear­ly-stage pa­tients whose non-small cell lung can­cer has not …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER